wonder drug

From todays ASX announcement it sounds like Neuren are potentially onto nothing short of an incredible wonder drug:

"Neuren is currently testing NNZ-2591 in a mouse model of multiple sclerosis, with results expected in the second half of 2014. NNZ-2591 has already shown efficacy in pre
-clinical models of Parkinson’s disease,stroke,traumatic brain injury, peripheral neuropathy,Fragile X Syndrome
and memory impairment.
The first claim of the new patent describes “
A method for relieving or alleviating a symptom of
cognitive impairment caused by a disease, injury, or condition in a mammal in need thereof,comprising: administering a pharmaceutically effective amount of cyclic Glycyl -2-Allyl Proline (cG-2-AllylP) to said mammal thereby providing relief from the symptom, where said disease is selected from the group consisting of Alzheimer’s disease, Huntington’s disease, Lewy Body disease, Dementia, cerebral atrophy, frontotemporal lobar degeneration, Pick’s disease, multi-infarct dementia, HIV infection, and Down’s syndrome, said injury is selected from the group consisting of neurotoxic injury, cerebral hypoxia/ischemia, traumatic brain injury, coronary artery bypass surgery,where said condition is normal aging, age
- related memory loss, memory impairment, cholinergic
hypofunction, vascular narrowing or blockage in the brain, neuroinflammation, mild cognitive impairment, and loss of synaptic plasticity."